STOCK TITAN

Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Avaí Bio (OTCQB: AVAI) and joint venture partner Austrianova will present new data on their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September. The presentation, delivered by Rahul Pawa on behalf of Klothonova, covers production of α-Klotho from encapsulated cells using Cell-in-a-Box® technology.

The work aims to restore circulating α-Klotho levels sustainably and explore therapeutic applications in aging and related conditions; featured conference speakers include Dr. Makoto Kuro-o.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • None.

Negative

  • None.

News Market Reaction – AVAI

-0.69%
1 alert
-0.69% News Effect

On the day this news was published, AVAI declined 0.69%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LAS VEGAS, April 7, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual Klotho Conference, which focuses on the future of Klotho-based therapies.

Representing Avaí Bio, Austrianova, and their joint venture, Klothonova, Rahul Pawa, Chief Production Officer at Austrianova, will deliver the presentation during the September conference. The presentation will focus on the production of the longevity protein α-Klotho from encapsulated cells, an approach designed to sustainably restore circulating α-Klotho levels and support potential therapeutic applications in aging and related conditions. (https://klothoconference.com/speakers)

The conference brings together a distinguished group of thought leaders, researchers, drug developers, clinicians, executives, analysts, and investors at the forefront of Klotho science and innovation. Featured speakers include key researchers and medical experts, including Dr. Makoto Kuro-o, the physician-scientist widely recognized for discovering the Klotho gene.

"We look forward to sharing the latest data from Klothonova's progress in α-Klotho production from encapsulated cells at this prestigious forum," said Brian Salmons, Chief Executive Officer of Austrianova. "We are honored to be invited by Harvard-trained neuroscientist Carmen Abrahams to participate in this conference and to present the latest data on production of α-Klotho using Cell-in-a-Box® alongside our peers."

About Avaí Bio, Inc.
Avaí Bio, Inc. is an emerging biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies.

About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies.

More information about Avaí Bio can be found at https://www.avaibio.com

You can also follow us on social media at:
https://x.com/AvaiBio
https://www.facebook.com/AvaiBio

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to

raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:
Avaí Bio, Inc.
info@avaibio.com

Logo: https://mma.prnewswire.com/media/2926240/5902955/Avai_Bio_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avai-bio-and-austrianova-to-present-latest-data-on-klotho-anti-aging-therapy-at-annual-klotho-conference-302735274.html

SOURCE Avai Bio, Inc.

FAQ

When will Avaí Bio (AVAI) present α-Klotho data at the Klotho Conference in 2026?

Avaí Bio will present α-Klotho data at the Second Annual Klotho Conference in September 2026. According to Avaí Bio, Rahul Pawa will deliver the presentation for Klothonova, highlighting production of α-Klotho from encapsulated cells using Cell-in-a-Box® technology.

Who will deliver the Klothonova presentation on α-Klotho at the 2026 conference for AVAI?

Rahul Pawa will deliver the Klothonova presentation on α-Klotho at the September 2026 conference. According to Avaí Bio, Pawa represents Austrianova and Klothonova and will discuss cell-based production methods and data on sustained α-Klotho production.

What will Avaí Bio (AVAI) present about its α-Klotho therapy at the conference?

Avaí Bio will present data on producing the longevity protein α-Klotho from encapsulated cells. According to Avaí Bio, the presentation focuses on sustainable restoration of circulating α-Klotho levels and potential therapeutic applications in aging and related conditions.

How does Avaí Bio (AVAI) describe the technology used to produce α-Klotho?

Avaí Bio describes using encapsulated cells and Cell-in-a-Box® technology to produce α-Klotho. According to Avaí Bio, this approach is designed to sustainably restore circulating α-Klotho and support potential therapeutic uses in age-related disorders.

Will the Avaí Bio (AVAI) presentation include notable Klotho researchers or speakers?

Yes, the conference program features leading Klotho researchers, including Dr. Makoto Kuro-o. According to Avaí Bio, the event gathers researchers, clinicians, drug developers, executives, and investors focused on advancing Klotho-based therapies and science.